Background: Several accelerated diagnostic protocols (ADPs) have been developed to allow emergency
C hest discomfort is a common presenting complaint at emergency departments (EDs; 6%-10% of all ED visits), 1, 2 and almost two-thirds of the patients presenting to ED with acute chest pain require further assessment and observation, incurring a high healthcare burden. 3 However, acute coronary syndrome (ACS) only accounts for 15% to 25% of these cases, and the majority of patients with chest pain are shown to be of noncardiac origin. [4] [5] [6] Several prediction models and clinical decision rules have been developed to allow ED physicians to identify the patients that have a low risk of an ACS and those who could be safely discharged directly from ED. [7] [8] [9] [10] [11] [12] [13] [14] The Vancouver Chest Pain Rule (VCPR), 15 the Emergency Department Assessment of Chest Pain Score (EDACS) accelerated diagnostic protocol (ADP), 16 and the Accelerated Diagnostic protocol to Assess Patients with chest pain using contemporary Troponins as the only biomarker (ADAPT) 17 are three decision rules that have shown to have high sensitivity and negative predictive values (NPVs) for identifying ACS/acute myocardial infarction (AMI).
Both VCPR and EDACS-ADP include components related to the chest pain characteristics as a part of their prediction model. 15, 16 However, some studies have shown the diagnostic value of pain characteristics to be limited, 18 due to the subjective nature of chest pain and reporting and ascertainment bias. The Third Universal Definition of MI incorporates patients with both typical and atypical chest pains, if they accompany biomarker and clinical findings suggestive of myocardial infarction. 19 Thus, it remains unclear how these decisions rules would perform without their chest pain characteristics component.
In this study, using the data from Providing Rapid Out of hospital Acute Cardiovascular Treatment (PROACT) 3 and 4 trials, 20, 21 we investigated the performance of a simplified version of VCPR and EDACS ADPs (without any pain characteristics component) and compared them with the operating characteristics of ADAPT-ADP in the same population.
METHODS
We conducted a retrospective study to assess the performance of three chest pain rules including a simplified version of the VCPR (sVCPR) and EDACS (sEDACS) ADPs and the ADAPT-ADP.
Participants
We pooled the subjects of PROACT-3 and -4 trials to develop a cohort of patients who presented to the ED via ambulance and were suspected to have acute cardiovascular disease. Both trials were approved by the health research ethic board at the University of Alberta. Eligible patients in PROACT-3 were adults over 18 years of age that activated prehospital emergency medical services (EMS) for symptoms of acute chest discomfort or dyspnea for which acute cardiovascular disease was deemed to be the most probable diagnosis by EMS personnel. The eligibility criteria for the PROACT-4 trial were the same as those for PROACT-3 with the exception that patients with dyspnea were not included in PROACT-4. Patients were excluded if they had documented ST-elevation on the initial 12-lead electrocardiogram (ECG) or with a prior diagnosis that was compatible with recurrent symptoms of dyspnea or chest discomfort from a noncardiovascular cause (e.g., chest trauma, severe asthma). The enrollment in PROACT-3 (n = 480) took place from November 2011 to December 2012 and it was from July 2013 to February 2015 in PROACT-4 (n = 601). Both trials enrolled patients directly in the ambulance and further care was provided in any of the five EDs in Edmonton, Alberta, Canada. In PROACT trials, the first ED visit was considered as the index visit and the other visits were excluded. Data abstraction for PROACT-3 and -4 trials was done by trained abstractors from the patient and/or medical chart. Patients were followed for 30 days after their index ED presentation. Alberta has a centralized electronic health record that captures all events regardless of location in the province of Alberta, allowing for any event to an urgent care, ED, or hospital to be identified. In PROACT-3 and -4, electronic record review was supplemented by phone calls to capture data on clinical outcomes-no additional events were captured via phone calls to patients. There was no loss to follow-up, and there was 100% capture of both primary and secondary endpoints in those trials. If there were multiple similar events for an individual patient in follow-up, only the first event was used.
The sVCPR
The VCPR was updated in 2013, using troponin as the only biomarker. 15, 22 The rule identifies patients to be eligible for early discharge if they have normal initial ECG, troponin < 99th percentile at 2 hours, no prior history of ACS or nitrate use, age < 50 years, and low-risk pain characteristics (reproducing pain by palpation and lack of pain radiation to neck, jaw, or arm; Data Supplement S1, Figure S1 [available as supporting information in the online version of this paper]). We simplified the new VCPR by removing the pain characteristics component (Figure 1 ).
The sEDACS-ADP
The EDACS-ADP incorporates the ECG and troponin (baseline and 2 hours) findings with EDACS score, which itself is composed of age, sex, known coronary artery disease (CAD), CAD risk factors, signs and symptoms like diaphoresis, radiation of pain to arms or shoulder, and occurrence or worsening of pain by inspiration or palpation. 16 A simplified (reduced and unweighted) version of EDACS model was proposed recently by the same group 23 with a diagnostic performance comparable to the original ADP, but a slightly smaller group of patients being labeled as low risk. We further simplified that ADP by removing the pain characteristics component leaving age, male sex, known CAD and three or more CAD risk factors, negative ECG, and negative baseline and 2-hour troponin test results as shown in Table 1 .
The ADAPT-ADP We used the original ADAPT-ADP as a benchmark to compare the performance of two other simplified models. This ADP identifies patients with a Thrombolysis in Myocardial Infarction (TIMI) risk score of 0, no ECG changes, and no positive baseline and 2-hour troponin results as low risk and eligible for early discharge from ED. 17 
TIMI Risk Score
Thrombolysis in Myocardial Infarction (TIMI) risk score was calculated using the following variables: age ≥ 65 years, three or more risk factors for CAD (family history of CAD, hypertension, hypercholesterolemia, diabetes, or being a current smoker), use of aspirin in the past 7 days, significant coronary stenosis, severe angina, ST-segment deviation of ≥0.05 mV on first ECG, and increased cardiac biomarker tests. Since we lacked the data on the significance of coronary stenosis (stenosis ≥ 50%), we estimated the rate using a variable developed from the combination of previous MI, previous percutaneous coronary intervention, and previous coronary artery bypass grafting. Patients with any of these conditions will receive the 1 point that is assigned to significant stenosis. All patients received a score of zero for the severity of angina.
Abnormal ECG
We used the ECG criteria as per each rule to determine those with abnormal ECG. All ECGs were read in a core lab at the Canadian VIGOUR Centre, Edmonton, Alberta. For evaluating the sVCPR, the abnormal ECG was defined as ST-segment elevation > 2 mm in two consecutive precordial leads or > 1 mm in two consecutive inferior or lateral leads or the following potential ischemic changes: any ST High risk 2. New ischemia on ECG 3. Either 0-or 2-h troponins positive ‡ CAD = coronary artery disease; ECG = electrocardiogram; EDACS = Emergency Department Assessment of Chest Pain Score; Simplified EDACS accelerated diagnostic protocol. *Known CAD: previous acute myocardial infarction, prior coronary artery bypass grafting, and previous percutaneous coronary intervention;
†CAD risk factors: smoking, hypertension, diabetes mellitus, hypercholesterolemia, family history of CAD.
‡In our analysis, we used only peak troponin, so if the peak troponin result was positive, this component was considered positive and vice versa.
ACADEMIC EMERGENCY MEDICINE • June 2017, Vol. 24, No. 6 • www.aemj.org depression > 2 mm in V1 or V2 (denoting posterior infarction); ST-depression > 0.5 mm in two contiguous leads; Q-waves in two contiguous leads, or T-wave inversion in two contiguous leads; left ventricular hypertrophy; paced rhythm; and left bundle branch block. For evaluating the operating characteristics of ADAPT-ADP and sEDACS-ADP, an abnormal ECG was defined as ST-segment depression of at least 0.05 mV in two contiguous leads (including reciprocal changes), T-wave inversion of at least 0.1 mV, or Q-waves ≥30 msec in width and ≥0.1 mV in depth in at least two contiguous leads, as per the original rules.
Biomarker Tests
In both PROACT-3 and PROACT-4 trials, the in-hospital troponin I tests were run on the Beckman AccuTnI assay (analytical sensitivity = 0.01 ng/mL, 99th percentile [male and female] = 0.04 ng/mL). In Edmonton region, in-hospital troponin does not clinically report (or make available) troponin values ≤ 0.1 ng/mL. The first in-hospital troponin tests were done at a median of 64 minutes after ED presentation. The point-of-care triage device (Alere) provided troponin I results in ambulance, using the Alere Cardio2 panel (analytical sensitivity = 0.01 ng/mL, 99th percentile [male and female] = 0.02 ng/mL). Positive troponin was defined as if any of the prehospital or in-ED troponin results were positive (>0.04 for in-hospital and >0.02 for prehospital testing). We also performed a sensitivity analysis, restricting the definition of positive troponin only to those with any positive in-ED troponin result.
Outcome
The primary outcome for assessing the operating characteristics of ADPs was 30-day major adverse cardiac events (MACE) including death, cardiac arrest, emergency revascularization procedure, cardiogenic shock, ventricular arrhythmia needing intervention, highdegree atrioventricular block needing intervention, and AMI. AMI was classified using the global taskforce recommendations which requires evidence of myocardial necrosis associated with clinical evidence of myocardial ischemia (ischemic symptoms, ECG changes, or imaging evidence). 19 The secondary outcome for assessing the operating characteristics of the ADPs was the diagnosis of ACS occurring within 30 days after ED presentation. In PROACT-3 and -4 trials, the 30-day events were captured by primary electronic and paper chart review. 20 , 21 The adjudication diagnoses were used for index ED visits, 24 and the ED diagnosis or the hospital discharge diagnosis was used for re-hospitalization events.
Statistical Analysis
Continuous variables were summarized using mean AE SD or median (interquartile range), as appropriate. For comparing the continuous variables between low-and high-risk groups according to each rule, the independent t test or Mann-Whitney U test were used. Categorical characteristics were presented as frequency (%) and the groups were compared using the Pearson chi-square test. The rate of patients who are eligible for early discharge was calculated and presented as frequency (%). While calculating ADP scores, the statistician was blinded to patient outcomes, and this was done after developing a statistical analytical plan with prespecified analyses. Each rule's diagnostic accuracy was assessed using sensitivity, specificity, positive predictive value and NPV with their exact confidence intervals (CIs). The diagnostic accuracy of sEDACS-ADP was evaluated using two different cut-points (3 and 4) suggested in the original risk model simplification study. 23 For all analyses, p < 0.05 denotes statistical significance, with no adjustment for multiple testing. SAS version 9.4 (SAS Institute) was used for all analyses.
RESULTS

Patient Characteristics
The study population consisted of 1,081 patients who presented by ambulance to the ED with symptoms suggestive of acute cardiovascular disease. Baseline characteristics of the overall population is shown in Table 2 . Median age was 67 years (33.8% age ≥ 75 years) with 53.2% of patients being male and 26.5, 60.6, and 30.8%, respectively, having a prior history of diabetes mellitus, hypertension, and MI. The median GRACE risk score 25 was 113 (25th, 75th percentiles = 87, 142). The adjudicated ED diagnosis was angina in 40 patients (3.7%), ACS in 189 patients (17.4%), acute heart failure in 47 patients (4.3%), and other diagnoses in 805 cases (74.4%).
A total of 765 patients (70.8%) were discharged directly from ED, based on the clinical judgment of the treating physician. Within 30 days after ED presentation, 222 patients (20.5%) had a diagnosis of ACS (Table 3) , and 150 (13.9%) cases of major Table 3 ). Seventy-eight (7.2%) and 156 patients (14.5%) had rehospitalization and re-ED visits, respectively.
Diagnostic Performance
The sVCPR identified 9.7% of patients (n = 105) as low risk (defined as normal initial ECG, negative troponins at 2 hours, no prior ACS or nitrate use, and age < 50 years; Data Supplement S1, Figure S2 ), while the rate was 13.3% (n = 144) and 24.2% (n = 262) with the sEDACS-ADP, respectively, when the cut-points of 3 and 4 were applied for the EDACS score component of the ADP. The ADAPT-ADP was only able to identify 4.1% of patients as low-risk, as very few patients in PROACT-3/4 had a TIMI score 0. The performance of different rules in identifying the ACS and MACE is summarized in Table 4 .
Primary Outcome
Both sVCPR and ADAPT-ADP had a sensitivity and NPV of 100% in identifying patients at a risk of 30-day MACE. When we considered the cut-point of 3 for sEDACS-ADP, the sensitivity and NPV were both 100% (Table 4) , and when we assigned the cut-point of 4 to sEDACS-ADP, 98% (95% CI = 94.3%-99.6%) of those who experienced some sort of MACE within 30 days after index ED presentation were labeled as not low risk and 98.8% (95% CI = 96.7%-99.7%) of those who labeled as low risk were free of 30-day MACE.
Secondary Outcome
Of 222 cases with an ACS diagnosis within 30 days after ED presentation, 99.1% (sensitivity, 95% CI = 96.8%-99.9%), 97.3% (95% CI = 94.2%-99.0%), and 98.7% (95% CI = 96.1-99.7) were identified by the sVCPR, sEDACS ≥ 3, and ADAPT-ADPs, respectively. Of those who were labeled as low risk using sVCPR, sEDACS ≥ 3 ADP, and ADAPT-ADP, respectively, 98.1, 95.8, and 93.3% were free of any 30-day ACS diagnosis. The factors that caused the patients to be labeled as high risk using each decision rule are presented in Data Supplement S1, Table S1 . Age was the factor that contributed the most in the risk identified by both VCPR and EDACS ADPs (92.5% of those who were not eligible for early discharge from ED according to VCPR had an age ≥ 50 and 90.8% of ineligible patients based on EDACS had an EDACS score ≥ 3, mainly driven by age). Patients who were identified as low risk according to these ADPs but had a diagnosis of ACS or experienced an adverse event within 30 days after ED visit or those who admitted to hospital despite a low-risk profile are described in detail in Data Supplement S1, Tables S2 and S3 . In sensitivity analysis, the performance of ADPs did not differ after restricting the definition of positive troponin only to those with any positive ED troponin result, except for sEDACS-ADP with the cut-point of 4 that showed a significantly lower sensitivity and NPV with ED troponins, which undermines its use at ED (Data Supplement S1, Tables S4A and S4B). In another sensitivity analysis, the performance of ADPs remained the same after restricting the study population to PROACT-4 trial (including only those with chest pain and excluding dyspnea). We also found that the randomization in PROACT trials have no effect on the results of this particular study.
DISCUSSION
In this study, we examined the diagnostic performance of a simplified version of two ADPs (i.e., VCPR and EDACS-ADP) in association with ADAPT ADP in identifying the very low-risk patients amenable for direct early ED discharge. These ADPs have a proven impact on reducing time to discharge from ED. 26, 27 If simplified by removing the subjective components, they will be easier to apply which can enhance their utility at triage in the ED. Both VCPR and EDACS-ADP performed well (i.e., high sensitivity and NPV) without their chest pain characteristics component. The sEDACS-ADP identified the largest group of lowrisk patients with excellent sensitivity and NPV rates.
The VCPR identifies low-risk patients to be those with normal arrival and 2-hour troponin levels, non-ischemic initial ECG, and no history of ACS or previous nitrate use, with an age < 50 years and with low-risk pain characteristics. 28 In the derivation/validation study, most patients with an ACS had an abnormal ECG or cardiac biomarker and only a few identified by pain characteristics and age alone (96.4% of patients with ACS age ≥ 50 years). Considering the low rate reported for characteristics of chest pain (48.4% for pain that radiates and does not increase with inspiration or palpation in the ACS group) and the low inter-rater reliability for these subjective variables, 28 we hypothesized that the rule will perform similarly without those subjective pain characteristics. Our findings support that hypothesis, as the simplified VCPR without pain characteristics as a part of the rule had a high sensitivity and NPV with rates of identified low-risk patients almost similar to previous external validation studies (13% identified as low risk with a sensitivity of 99.1% and NPV of 98.6%). 22 According to ADAPT-ADP results, patients with TIMI score 0, no ischemic ECG changes, and no positive troponin results on two assessments 2 to 3 hours apart were shown to have a 0% rate of 30-day major cardiovascular events, which was similar to previous studies (sensitivity and NPV of 99.7%). 17 Nevertheless, this ADP was only able to identify 4.1% of patients as low risk, which makes it an unsuitable ADP to be used in populations with higher than general risk level, such as our community-based population.
The sEDACS-ADP was able to identify a larger group of low-risk patients when the cut-point of 4 rather than 3 was used for the EDACS score component of the model (24.2% vs. 13.3%), while this increase in the number of low-risk patients identified was at the cost of an increase in the likelihood of missing cases with potential risk of 30-day MACE (1.14% compared to 0%). The decision about which cut-point to be used highly depends on the healthcare systems' and individual care providers' preferences. Whether their priority is not to miss any case at a risk of MACE or to decrease the costs that are incurred by prolonged ED stays, unnecessary hospital admissions, and unnecessary diagnostic tests. In general, the majority of ED physicians have been shown to prefer to have a missing rate ≤ 1%, 29 while studies have reported the current statistics to be a bit higher than that in patients who are receiving the standard ED care for ACS. [30] [31] [32] [33] [34] In the main analysis of this study, both prehospital and ED troponins were used to identify those with elevated troponins; however, the sensitivity analysis, restricting the definition of elevated troponin only to those with elevated ED troponins revealed a less desirable performance for sEDACS ADP when the cutpoint of 4 was used rather than 3 (Data Supplement S1, Table S4 ), which undermines the use of that cutpoint and makes it unfit for use in clinical practice. Different model performance when using ED troponins rather than prehospital point-of-care troponin results could be attributed to the use of a more sensitive troponin test in ambulance compared to the assay that was used in ED.
Given that roughly 70% of patients in our population were discharged directly from ED, some may consider the performance of these ADPs to be of less than ideal value, nevertheless it should be noted that this is not just about ED discharge. The main purpose is to identify those who are eligible for a "safe early discharge" within 2 hours. Even those who were discharged from ED in our study were observed for an average time of 9 hours at ED; however, if we were using these ADPs, at least 10% to 15% of patients could be discharged safely within 2 hours of their ED visit.
The troponin assays we used in this study were not high-sensitive troponin tests. Cullen et al. 22 in a validation study of the new VCPR used both sensitive and high-sensitive troponin (hs-TnI) assays and reported no difference between these two assays in terms of the diagnostic performance of the rule. This is discrepant with other studies highlighting improved diagnostic performance of clinical pathways with hs-Tn assays. 35, 36 Further description of the clinical effectiveness of ADPs in real-world practice settings needs to be described.
LIMITATIONS
There are both limitations and strengths to our study. We lacked the data regarding the characteristics of pain in our database, so it was impossible to compare the diagnostic accuracy and performance of the original ADPs with their simplified versions. We did not have the data on severity of angina as defined in the TIMI score (i.e., ≥2 angina events during the past 24 hours or persisting discomfort); therefore, we assigned a score of zero for all patients and this could lead to an underestimation of the actual risk. Hence, even fewer patients may have been eligible for early discharge using ADAPT-ADP. The difference between PROACT population and the derivation cohorts of these accelerated diagnostic pathways is noted (e.g., EMS-transported vs. ED-presented, patients identified by EMS personnel vs. physicians, healthcare system and setting), as the PROACT populations may have a slightly higher overall risk based on baseline characteristics and event rates and the rate of patients who were ultimately discharged from the ED directly (70%) may differ in other cohorts. However, a lower-risk population may have a different (and likely higher) NPV for determining who is eligible for early safe discharge. To reach definitive conclusions, the simplified rules excluding chest pain components should be validated formally in studies with adequate sample sizes, ideally in a randomized trial and supported by appropriate statistical modeling. However, having a broad contemporary cohort of patients who presented with ambulance to the ED with suspected cardiovascular disease, the use of core-lab read ECGs that provides a more robust and systematic look at the ECGs, and the use of centrally adjudicated diagnoses are strengths of this study.
CONCLUSION
Both Vancouver Chest Pain Rule and Emergency Department Assessment of Chest Pain Score accelerated diagnostic protocol performed well without their chest pain characteristics components. The findings could refine the need to use chest pain characteristics in accelerated diagnostic protocols for the purpose of risk stratifying patients in the ED; hence, it could be practice-changing. The simplified Emergency Department Assessment of Chest Pain Score accelerated diagnostic protocol and Accelerated Diagnostic protocol to Assess Patients with chest pain using contemporary Troponins as the only biomarker accelerated diagnostic protocol had, respectively, the best and worst diagnostic performance in identifying the low-risk population. Further studies are suggested to explore the performance of accelerated diagnostic protocols when these simplified accelerated diagnostic protocols are combined with high-sensitive troponin assays.
